- Companies
- Neuraxis
Neuraxis Valuation Multiples
Neuraxis is valued at $60M as of November 2026, a 7.6x revenue multiple. In the last 12 months, Neuraxis revenue was $7M and Neuraxis EBITDA was ($8M).
Neuraxis Overview
About Neuraxis
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its’ proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
Founded
2011
HQ
Employees
21
Website
Financials (LTM)
EV
$56M
Valuation Multiples
Start free trialNeuraxis Financials
Neuraxis reported last 12-month revenue of $7M and negative EBITDA of ($8M).
In the same LTM period, Neuraxis generated $6M in gross profit, ($8M) in EBITDA losses, and had net loss of ($13M).
Neuraxis P&L
In the most recent fiscal year, Neuraxis reported revenue of $4M and EBITDA of ($8M).
Neuraxis is unprofitable as of last fiscal year, with gross margin of 84%, EBITDA margin of (215%), and net margin of (219%).
Financial data powered by Morningstar, Inc.
Neuraxis Stock Performance
Neuraxis has current market cap of $60M, and enterprise value of $56M.
Market Cap Evolution
Neuraxis' stock price is $4.22.
Neuraxis has an EPS (earnings per share) of $-0.55.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $56M | $60M | 0.0% | - | - | - | $-0.55 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNeuraxis Valuation Multiples
Neuraxis trades at 7.6x EV/Revenue multiple, and (6.9x) EV/EBITDA.
Neuraxis Financial Valuation Multiples
As of November 22, 2026, Neuraxis has market cap of $60M and EV of $56M.
Neuraxis has a P/E ratio of (4.6x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Neuraxis Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Neuraxis Margins & Growth Rates
Neuraxis grew revenue by 119% and EBITDA by 7% in the last fiscal year.
In the most recent fiscal year, Neuraxis reported gross margin of 84%, EBITDA margin of (215%), and net margin of (219%).
Neuraxis Margins
Neuraxis Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Neuraxis Operational KPIs
Neuraxis' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.5M for the same period.
Neuraxis' Rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Neuraxis' Rule of X is 191% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Neuraxis Competitors
Neuraxis competitors include Nutriband, Pangaea Oncology, Hyperfine, Agfa-Gevaert, Applied BioCode, LENSAR, Remedi, Klea, Creo Medical Group and Nexstim.
Most Neuraxis public comparables operate across Medical Devices, Digital Therapeutics, BioTech and HealthTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $2M | ($8M) | 27.8x | - | (7.1x) | - | |||
| $16M | ($1M) | 3.9x | 3.7x | (60.4x) | (19.7x) | |||
| $14M | ($36M) | 2.5x | 1.7x | (1.0x) | (1.1x) | |||
| $1.2B | ($8M) | 0.2x | 0.2x | (26.1x) | 2.7x | |||
| $14M | ($5M) | 3.5x | - | (10.1x) | - | |||
| $58M | ($30M) | 1.0x | 1.0x | (2.0x) | 12.2x | |||
| $11M | $2M | 5.7x | - | 26.0x | - | |||
| $24M | $6M | 2.3x | - | 10.2x | - | |||
This data is available for Pro users. Sign up to see all Neuraxis competitors and their valuation data. Start Free Trial | ||||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Neuraxis
| When was Neuraxis founded? | Neuraxis was founded in 2011. |
| Where is Neuraxis headquartered? | Neuraxis is headquartered in United States. |
| How many employees does Neuraxis have? | As of today, Neuraxis has over 21 employees. |
| Is Neuraxis publicly listed? | Yes, Neuraxis is a public company listed on NYSE American. |
| What is the stock symbol of Neuraxis? | Neuraxis trades under NRXS ticker. |
| When did Neuraxis go public? | Neuraxis went public in 2023. |
| Who are competitors of Neuraxis? | Neuraxis main competitors include Nutriband, Pangaea Oncology, Hyperfine, Agfa-Gevaert, Applied BioCode, LENSAR, Remedi, Klea, Creo Medical Group, Nexstim. |
| What is the current market cap of Neuraxis? | Neuraxis' current market cap is $60M. |
| What is the current revenue of Neuraxis? | Neuraxis' last 12 months revenue is $7M. |
| What is the current revenue growth of Neuraxis? | Neuraxis revenue growth (NTM/LTM) is 102%. |
| What is the current EV/Revenue multiple of Neuraxis? | Current revenue multiple of Neuraxis is 7.6x. |
| Is Neuraxis profitable? | No, Neuraxis is not profitable. |
| What is the current EBITDA of Neuraxis? | Neuraxis has negative EBITDA and is not profitable. |
| What is Neuraxis' EBITDA margin? | Neuraxis' last 12 months EBITDA margin is (110%). |
| What is the current EV/EBITDA multiple of Neuraxis? | Current EBITDA multiple of Neuraxis is (6.9x). |
| What is the current FCF of Neuraxis? | Neuraxis' last 12 months FCF is ($6M). |
| What is Neuraxis' FCF margin? | Neuraxis' last 12 months FCF margin is (87%). |
| What is the current EV/FCF multiple of Neuraxis? | Current FCF multiple of Neuraxis is (8.7x). |
| How many companies Neuraxis has acquired to date? | Neuraxis hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Neuraxis has invested to date? | Neuraxis hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Neuraxis
Lists including Neuraxis
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




